RU2001131894A - METHOD FOR INCREASING EFFICIENCY OF ANTITUMOR AGENTS - Google Patents

METHOD FOR INCREASING EFFICIENCY OF ANTITUMOR AGENTS

Info

Publication number
RU2001131894A
RU2001131894A RU2001131894/14A RU2001131894A RU2001131894A RU 2001131894 A RU2001131894 A RU 2001131894A RU 2001131894/14 A RU2001131894/14 A RU 2001131894/14A RU 2001131894 A RU2001131894 A RU 2001131894A RU 2001131894 A RU2001131894 A RU 2001131894A
Authority
RU
Russia
Prior art keywords
agent
erythropoietin
cisplatin
antitumor
increasing
Prior art date
Application number
RU2001131894/14A
Other languages
Russian (ru)
Other versions
RU2271829C2 (en
Inventor
М. Стивен ПАЙВЕР
Дэвид Ф. СИЛВЕР
Original Assignee
Хелт Рисерч, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/300,124 external-priority patent/US6171620B1/en
Application filed by Хелт Рисерч, Инк. filed Critical Хелт Рисерч, Инк.
Publication of RU2001131894A publication Critical patent/RU2001131894A/en
Application granted granted Critical
Publication of RU2271829C2 publication Critical patent/RU2271829C2/en

Links

Claims (13)

1. Способ повышения эффективности противоопухолевого средства, включающий стадии введения субъекту, нуждающемуся в лечении, (а) химиотерапевтически активного количества противоопухолевого средства, и (б) средства для повышения гематокрита, где сочетание противоопухолевого средства и средства для повышения гематокрита оказывает синергический противоопухолевый эффект.1. A method for increasing the effectiveness of an antitumor agent, comprising the steps of administering to a subject in need of treatment (a) a chemotherapeutically active amount of an antitumor agent, and (b) an agent for increasing hematocrit, where the combination of an antitumor agent and an agent for increasing hematocrit has a synergistic antitumor effect. 2. Способ по п.1, где противоопухолевое средство представляет собой соединение платины.2. The method according to claim 1, where the antitumor agent is a platinum compound. 3. Способ по п.2, где противоопухолевое средство представляет собой малонатное соединение платины.3. The method according to claim 2, where the antitumor agent is a malonate compound of platinum. 4. Способ по п.3, где малонатное соединение платины выбрано из группы, состоящей из цисплатина и карбоплатина.4. The method according to claim 3, where the platinum malonate compound is selected from the group consisting of cisplatin and carboplatin. 5. Способ по п.4, где соединением платины является цисплатин.5. The method according to claim 4, where the platinum compound is cisplatin. 6. Способ по п.4, где соединением платины является карбоплатин.6. The method according to claim 4, where the platinum compound is carboplatin. 7. Способ по п.1, где средство для повышения гематокрита выбрано из группы, состоящей из эритропоэтина и эритропоэтин-подобного вещества.7. The method according to claim 1, where the agent for increasing hematocrit is selected from the group consisting of erythropoietin and erythropoietin-like substance. 8. Способ по п.7, где средством для повышения гематокрита является эритропоэтин.8. The method according to claim 7, where the means for increasing hematocrit is erythropoietin. 9. Способ по п.8, где средством для повышения гематокрита является эритропоэтин-подобное вещество.9. The method of claim 8, wherein the agent for increasing hematocrit is an erythropoietin-like substance. 10. Способ по п.1, где противоопухолевым средством является цисплатин, а средством для повышения гематокрита является эритропоэтин.10. The method according to claim 1, where the antitumor agent is cisplatin, and the agent for increasing hematocrit is erythropoietin. 11. Способ по п.10, где цисплатин вводят в дозах от 25 до 300 мг/м2.11. The method according to claim 10, where cisplatin is administered in doses from 25 to 300 mg / m 2 . 12. Способ по п.11, где цисплатин назначается в дозах от 50 до 100 мг/м2.12. The method according to claim 11, where cisplatin is prescribed in doses from 50 to 100 mg / m 2 . 13. Способ по п.1, где средство для повышения гематокрита вводят до введения противоопухолевого средства.13. The method according to claim 1, where the agent for increasing hematocrit is administered before the administration of the antitumor agent.
RU2001131894/14A 1999-04-27 2000-04-24 Method for enhancing effectiveness of antitumor agents RU2271829C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
US09/300,124 1999-04-27

Publications (2)

Publication Number Publication Date
RU2001131894A true RU2001131894A (en) 2003-08-27
RU2271829C2 RU2271829C2 (en) 2006-03-20

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001131894/14A RU2271829C2 (en) 1999-04-27 2000-04-24 Method for enhancing effectiveness of antitumor agents

Country Status (18)

Country Link
US (3) US6171620B1 (en)
EP (1) EP1212068A4 (en)
JP (1) JP2002542296A (en)
KR (1) KR100693796B1 (en)
CN (1) CN1188137C (en)
AU (1) AU781301B2 (en)
BG (1) BG64940B1 (en)
BR (1) BR0010082A (en)
CA (1) CA2368618C (en)
HU (1) HUP0200840A3 (en)
IL (1) IL146012A0 (en)
MX (1) MXPA01010899A (en)
NO (1) NO20015227L (en)
NZ (1) NZ514521A (en)
PL (1) PL350918A1 (en)
RU (1) RU2271829C2 (en)
WO (1) WO2000064455A1 (en)
ZA (1) ZA200108012B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531179A (en) 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン Formulations and methods of using nitric oxide mimetics for malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20040266806A1 (en) 2003-04-08 2004-12-30 Sanghvi Suketu P. Pharmaceutical formulation
DE10361813A1 (en) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Using hematopoietic growth factors for structural regeneration of tissue, useful e.g. for treating liver damage and wounds
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (en) * 2005-03-07 2009-02-17 Univ Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration.
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
EP3064503A1 (en) 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
DK2565195T3 (en) 2007-03-29 2015-06-29 Wyeth Llc PERIPHERAL OPIOID RECEPTOR AND ANTAGONISTS AND USES THEREOF
WO2008121352A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
CN101959892B (en) 2008-02-06 2014-01-08 普罗热尼奇制药公司 Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
WO2009140382A2 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (en) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Pharmaceutical set and application of erythropoietin and of the Bruton kinase inhibitor
JPWO2019083023A1 (en) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 Compositions for use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (en) * 1988-03-03 1997-07-16 中外製薬株式会社 Bone marrow dysfunction anemia treatment
JPH1067678A (en) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd Medicinal composition for treating liver disease
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Similar Documents

Publication Publication Date Title
RU2001131894A (en) METHOD FOR INCREASING EFFICIENCY OF ANTITUMOR AGENTS
CA2368618A1 (en) Method of enhancing the efficacy of anti-tumor agents
RU99112577A (en) NEW APPLICATION OF 1,3-PROPANDIOL DERIVATIVES
RU2001111880A (en) COMPOSITIONS FOR ORAL ADMINISTRATION CONTAINING LUFENURON AND NITENPIRA FOR THE STRUGGLE AGAINST Fleas
RU95106821A (en) Cyclopeptides, method of their synthesis, pharmaceutical composition and method of its preparing
RU93032613A (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION
Ohtsuka et al. Treatment of intractable childhood epilepsy with high‐dose valproate
RU95101385A (en) Products containing g-csf and tnf-binding protein
AU7971994A (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
KR950016760A (en) Hemorrhoids Treatment
RU97120700A (en) NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR
RU96103685A (en) 1,2,5-TIADIAZOLIC DERIVATIVES OF INDOLALALKYL-PYRIDINIL-PYRIMIDINIL-PIPERAZINES, METHOD OF TREATMENT OR PREVENTION OF THE DEVELOPMENT OF VASCULAR HEADACHE AND PHARMACEUTICAL COMPOSITION
Splinter et al. Phase I study of alpha-difluoromethylornithine and methyl-GAG
ATE192926T1 (en) COMPOSITION CONTAINING FLAVOPEREIRINE AND ITS USE IN THE TREATMENT AGAINST HIV VIRUSES
US20020071814A1 (en) Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
RU99118510A (en) COMPOSITION FOR THE TREATMENT OR PREVENTION OF PROSTATE CANCER
JP2008528609A (en) Periodontal disease treatment and prevention composition and method of use
RU2000125095A (en) FUNGICIDAL COMPOSITION INCLUDING BENZOILPHENYL UREA
RU2019180C1 (en) Remedy for treatment of hypodermic fibrosarcoma and method of its preparation
Jortay et al. Regional chemotherapy of maxillofacial malignant melanoma with intracarotid artery infusion of DTIC
RU2002107675A (en) MEDICINES CONTAINING XENOGENOUS OLIGO OR / AND POLYRIBONUCLEOTIDES
JPS5639019A (en) Antiviral agent
RU2002115270A (en) Compounds and method for treating pain
RU95105563A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GASTROENTEROLOGICAL DISEASES AND METHOD OF TREATMENT OF THESE DISEASES
RU99101827A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRAL DISEASES